দেশ: নিউ জিলণ্ড
ভাষা: ইংরেজি
সূত্র: Medsafe (Medicines Safety Authority)
Cyclizine hydrochloride 50mg
AFT Pharmaceuticals Ltd
Cyclizine hydrochloride 50 mg
50 mg
Tablet
Active: Cyclizine hydrochloride 50mg Excipient: Acacia Lactose monohydrate Magnesium stearate Potato starch Purified water
Blister pack, Al-PVC blisters, Dispensary Only Pack, 10 tablets
Restricted
Prescription
Srikem Laboratories Pvt Ltd
Nausicalm is indicated for the prevention and treatment of nausea and vomiting including motion sickness, nausea and vomiting caused by narcotic analgesics and by general anaesthetics in the post-operative period and radiotherapy, especially for breast cancer since cyclizine does not elevate prolactin levels. Nausicalm may be of value in relieving vomiting and attacks of vertigo associated with Meniere's disease and other forms of vestibular disturbance.
Package - Contents - Shelf Life: Blister pack, Al-PVC blisters - 10 tablets - 36 months from date of manufacture stored at or below 30°C - Blister pack, Al-PVC blisters - 50 tablets - 36 months from date of manufacture stored at or below 30°C - Blister pack, Al-PVC blisters - 100 tablets - 36 months from date of manufacture stored at or below 30°C
2005-02-07
NEW ZEALAND DATA SHEET NAUSICALM Tablets SPC v 1.0 January 2017 Page 1 of 7 1 PRODUCT NAME NAUSICALM Cyclizine hydrochloride 50 mg tablet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 50 mg cyclizine hydrochloride Excipient with known effect: Lactose monohydrate For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM White, circular, biconvex, uncoated tablets with a score line on one side, plain on the other. The tablets can be divided into two halves. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS NAUSICALM is indicated for the prevention and treatment of nausea and vomiting including • motion sickness. • nausea and vomiting caused by narcotic analgesics and by general anaesthetics in the post-operative period. • nausea and vomiting associated with radiotherapy, especially for breast cancer since cyclizine does not elevate prolactin levels. NAUSICALM may be of value in relieving vomiting and attacks of vertigo associated with Meniere’s disease and other forms of vestibular disturbance. 4.2 DOSE AND METHOD OF ADMINISTRATION Route of administration: Oral Adults and children over 12 years: one tablet up to three times daily Children 6 – 12 years: half a tablet up to three times daily Children under 6 years: Not recommended Use in the Elderly: There have been no specific studies of cyclizine in the elderly. Experience has indicated that normal adult dosage is appropriate. NEW ZEALAND DATA SHEET NAUSICALM Tablets SPC v 1.0 January 2017 Page 2 of 7 4.3 CONTRAINDICATIONS NAUSICALM should not be given to individuals with known hypersensitivity to cyclizine or to any of the excipients listed in section 6.1. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE Potential anticholinergic effects As with other anticholinergic agents, cyclizine should be used with caution and appropriate monitoring in patients with glaucoma, obstructive disease of the gastrointestinal tract and in males with possible prostatic hypertrophy. Heart failure Cyclizine should be used with caution in patients w সম্পূর্ণ নথি পড়ুন